Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Podophyllotoxin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1975

[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].

The new semisynthetic epipodophyllotoxin VP 16-213 has been tested for antitumor activity and toxicity in a non-randomized phase II trial. The study included 33 patients with solid tumors and acute leukemias. The drug was given in 5-day courses every 3 weeks, parenterally for the first 2 courses and thereafter orally. Subjectively VP 16-213 was well tolerated in both i.v. and oral administration, but almost universally induced leukothrombopenia and hair loss. The best results were achieved in 12 patients with oat cell carcinoma of the lung (4 good and 4 less good responses). Remissions of lesser quality were also observed in anaplastic lung cancer, ovarian carcinoma and acute myelomonocytic leukemia. VP 16-213 possesses proven, clinically valuable cytostatic activity against various human neoplasms. Complementary studies to establish its optimum dosage and administration, and its place in combination chemotherapy, are in progress.

Adenocarcinoma↗
PubMed1986

[Comparative studies between 0.5 percent podophyllotoxin preparations (Condyline) and 20 percent podophyllin dissolved in alcohol, in the therapy of raised condylomas].

We report on a comparative clinical study on 0.5% condyline solution and cream versus 20% podophyllin solution given to 75 patients suffering from condylomata acuminata. Podophyllin was applied once a week during a 6 weeks hospital care; therapy with condyline was carried out by the patients at home twice a day during 4 consecutive days. After therapy, full remission was obtained in 17 out of the 25 patients (68%) treated with condyline solution, in 17 out of the 26 patients (65%) treated with condyline cream, and in 8 out of the 24 patients (38%) treated with podophyllin. 8 biopsies taken from 6 patients did not reveal any atypical "podophyllin cells". Part of the patients showed transitional irritation, sometimes with erosions, which occurred more often after condyline treatment than after podophyllin therapy. This side effect of the cytotoxic drug, however, is to be expected.

Adolescent↗
PubMed1985

The Kidney Invasion Test: an assay allowing macroscopic quantification of malignant invasion in vivo. Comparison between the microtubule inhibitor tubulozole and the podophyllotoxin congener etoposide (VP-16-213).

When MO4 tumor fragments were implanted under the renal capsule of syngeneic or allogeneic mice, invasion of the renal parenchyma was observed. Inhibition of invasion by the microtubule inhibitor tubulozole could be macroscopically quantified and compared with the invasion permissive drug etoposide (VP-16-213). These results have been histologically confirmed, and the use of this assay in vivo for the rapid macroscopical screening of compounds with potential anti-invasive properties is discussed.

Animals↗